Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$13.46 +0.2%	$10.14	$2.31 ▼ $14.70	$64.88M	-0.59	52,938 shs	43,507 shs
MDWD MediWound	$17.60 +1.2%	$19.29	$14.14 ▼ $22.50	$190.28M	0.21	75,790 shs	79,455 shs
SXTC China SXT Pharmaceuticals	$1.57	$1.68	$0.95 ▼ $7.84	$182.16M	1.24	40,649 shs	17,398 shs
VTYX Ventyx Biosciences	$2.74 +3.4%	$2.63	$0.78 ▼ $3.39	$195.39M	0.97	777,227 shs	462,223 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	0.00%	-3.65%	+13.01%	+29.30%	+217.45%
MDWD MediWound	0.00%	-2.76%	-15.63%	-13.60%	-6.08%
SXTC China SXT Pharmaceuticals	0.00%	-2.48%	-3.09%	+1.29%	-77.18%
VTYX Ventyx Biosciences	0.00%	-3.18%	-14.38%	+62.13%	+39.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	0.7097 of 5 stars	0.0	3.0	2.7	1.7	0.0
MDWD MediWound	1.4375 of 5 stars	3.4	1.0	0.9	0.8	0.6
SXTC China SXT Pharmaceuticals	0.746 of 5 stars	0.0	3.0	3.3	0.0	0.6
VTYX Ventyx Biosciences	2.2309 of 5 stars	3.3	3.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
MDWD MediWound	2.80	Moderate Buy	$32.25	83.24% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
VTYX Ventyx Biosciences	2.50	Moderate Buy	$7.50	173.72% Upside

Current Analyst Ratings Breakdown

Latest COEP, MDWD, VTYX, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	$263.56K	246.16	N/A	N/A	$1.47 per share	9.16
MDWD MediWound	$19.86M	9.58	N/A	N/A	$1.86 per share	9.46
SXTC China SXT Pharmaceuticals	$1.74M	104.69	N/A	N/A	$21.35 per share	0.07
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$2.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	-$135.12M	-$1.68	N/A	N/A	N/A	N/A	-48.89%	-44.87%	11/6/2025 (Estimated)

Latest COEP, MDWD, VTYX, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/7/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	-$0.38	+$0.07	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.02	0.83	0.82
MDWD MediWound	N/A	1.48	1.99
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
VTYX Ventyx Biosciences	N/A	19.12	19.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
MDWD MediWound	46.83%
SXTC China SXT Pharmaceuticals	5.02%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
MDWD MediWound	9.20%
SXTC China SXT Pharmaceuticals	3.95%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	4.82 million	3.65 million	Not Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
VTYX Ventyx Biosciences	30	71.31 million	60.98 million	Optionable

COEP, MDWD, VTYX, and SXTC Headlines

Recent News About These Companies

H.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)

August 23 at 6:20 PM | theglobeandmail.com

Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)

August 23 at 6:20 PM | theglobeandmail.com

Ventyx Biosciences Reports Decreased Losses in 2025

August 15, 2025 | msn.com

3 Best Stocks to Buy Now, 8/11/2025, According to Top Analysts

August 11, 2025 | msn.com

Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"

August 10, 2025 | marketbeat.com

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 9, 2025 | finance.yahoo.com

Ventyx (VTYX) Q2 Net Loss Drops 16%

August 9, 2025 | theglobeandmail.com

Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

August 2, 2025 | marketbeat.com

Monaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

July 30, 2025 | marketbeat.com

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

July 22, 2025 | uk.finance.yahoo.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COEP, MDWD, VTYX, and SXTC Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$13.46 +0.03 (+0.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.50 +0.04 (+0.30%)

As of 08/22/2025 07:19 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

MediWound NASDAQ:MDWD

$17.60 +0.21 (+1.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.58 -0.02 (-0.11%)

As of 08/22/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.57 0.00 (0.00%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.57 +0.00 (+0.25%)

As of 08/22/2025 04:12 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Ventyx Biosciences NASDAQ:VTYX

$2.74 +0.09 (+3.40%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.76 +0.02 (+0.73%)

As of 08/22/2025 07:46 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time